Skip to main content

Table 2 Published Susceptibility for HIV-1 Isolates with Two NNRTI-Associated Drug-Resistance Mutations (DRMs) Ordered by Frequency in the ART-Naïve Dataseta

From: Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

NNRTI DRMb

Number of sequences

Fold-reduced susceptibility median #tests

K103N, P225H

58

7.92

L100I, K103N

32

5.79

K101E, G190A

18

 < 3.04

K103N, Y181C

16

3.85

K103N, V108I

15

4.62

A98G, K103N

15

41

K103N, G190A

14

 < 3.04

Y181C, G190A

10

3.53

A98G, Y181C

9

3.31

K103N, Y188L*

8

 > 641

V106I, Y188L*

5

 > 641

V108I, Y181C

5

6.92

V106A, F227L*

4

 > 641

V106A, P225H*

2

 > 641

V106M, F227C*

1

 > 642

  1. aThe table includes phenotypic susceptibility data published by the Merck Research Laboratory
  2. bSusceptibility data were not available for 214 sequences including 57 that contained ≥ 1 canonical DOR DRM or V106M, Y181V, or G190S/E. The remaining 157 sequences did not contain a DRM that was individually associated with ≥  3.0-fold reduced DOR susceptibility. Mutation patterns followed by an asterisk containing ≥ 1 canonical doravirine-resistance mutation
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us